COTA provides oncology research and development, regulatory, commercial, and HEOR teams with detailed real-world patient data to discover new treatment protocols and transform cancer care.
Real, longitudinal patient data across dozens of patient subgroups and oncology disease areas help pharmaceutical and biotech companies optimize their research, development, and commercialization strategies.
COTA data includes over 2M+ patients across a variety of cancer diagnoses, treatment settings, and demographics and is regularly maintained and updated to ensure quality, accuracy, relevance, and linkability.
Get access to a massive database of longitudinal real-world outcomes datasets curated to specific cancer types, subpopulations, or broad population research.
Get expert clinical insights, study design support, and statistical analysis.
Explore our collection of clinical research, recent press, podcasts, and more.
NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical…
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an…
For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power research that will improve care and expand treatment options for patients. And…
Partner with COTA for the highest-quality curated cancer patient datasets.